SEARCH

SEARCH BY CITATION

References

  • 1
    Seki S, Habu Y, Kawamura T, et al. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 2000;174:3546.
  • 2
    Kadowaki N, Liu YJ. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol 2002;63:112632.
  • 3
    Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepatitis 2005;12:3845.
  • 4
    Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:58394.
  • 5
    Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J Virol 2004;78:786773.
  • 6
    Yu XL, Lv LP, Yan F, et al. Effect of hepatitis B virus attack on the expression of interferon-beta in hepatocytes. Bull Acad Mil Med Sci 2011;35:58792.
  • 7
    Bonjardim CA, Ferreira PCP, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett 2009;122:111.
  • 8
    Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011;60:4753.
  • 9
    Shi CC, Xie Q, Zhao GD, et al. PD-L1 expression in hepatocytes and the regulation by interferon-α and hepatitis B virus. Chin Hepatol 2010;15:235.
  • 10
    Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001;194:175566.
  • 11
    Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002;169:518895.
  • 12
    Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76:107027.
  • 13
    Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:92130.
  • 14
    Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response–more than just antiviral cytokines. Mol Immunol 2005;42:86977.
  • 15
    Touzot M, Soumelis V, Asselah T. A dive into the complexity of type I interferon antiviral functions. J Hepatol 2012;56:7268.
  • 16
    Peltekian C, Gordien E, Garreau F, et al. Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice. J Hepatol 2005;43:96572.
  • 17
    Chai Y, Huang H-L, Hu D-J, et al. IL-29 and IFN-α regulate the expression of MxA, 2′,5′-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells. Mol Biol Rep 2010;38:13943.
  • 18
    Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interferon Cytokine Res 2011;31:718.
  • 19
    Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303:1829.
  • 20
    Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002;76:35704.
  • 21
    Alsharifi M, Mullbacher A, Regner M. Interferon type I responses in primary and secondary infections. Immunol Cell Biol 2008;86:23945.
  • 22
    Liang WF. Study on the anti-hepatitis B virus with Peg-IFNα-2a and IFNα-2a in vitro and in vivo [Dissertation]. Guangzhou: First Military Medical University, 2007.
  • 23
    Zeng WQ. Observation on the effect of Pegasys in combination with adefovir dipivoxil on hepatitis B patients. China Trop Med 2006;6:8223.
  • 24
    Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNγ signaling—Does it mean JAK–STAT? Cytokine Growth Factor Rev 2008;19:38394.
  • 25
    Zhang XH, Wu GT, Zhou P. Clinical anti-HBV effect by famciclovir in combination with interferon-γ. Chin J Mod Appl Pharm 2005;22:2624.
  • 26
    Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:2361.
  • 27
    Chisari FV, Hepatitis B. virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:14973.
  • 28
    Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:666974.
  • 29
    Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012;25:14263.
  • 30
    Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:16070.
  • 31
    Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 2011;31(Suppl. 1):11721.
  • 32
    Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49:S17484.
  • 33
    Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007;13:12540.
  • 34
    Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004;15:299305.
  • 35
    Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007;11:86992. ix.
  • 36
    Genin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009;29:343550.
  • 37
    Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3beta regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 2010;33:87889.
  • 38
    Levy DE, Marie I, Smith E, Prakash A. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002;22:8793.
  • 39
    Heydtmann M. Macrophages in hepatitis B and hepatitis C virus infections. J Virol 2009;83:2796802.
  • 40
    Cui GY, Diao HY. Recognition of HBV antigens and HBV DNA by dendritic cells. Hepatobiliary Pancreat Dis Int 2010;9:58492.
  • 41
    Qian ZP, Li N, Zheng ZP, et al. HBV inhibits the expressions of TLR3, Mda-5 and RIG-I in macrophage cells. Chin Hepatol 2010;15:4258.
  • 42
    An BY, Xie Q, Wang H, et al. Expression and significance of interferon regulatory factor 3 of peripheral blood dendritic cells in HBV-infected patients. World Chin J Digestol 2008;16:18739.
  • 43
    Wieland SF, Vega RG, Muller R, et al. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003;77:122736.
  • 44
    Hu J. Induction of cytokine on hepatocytes by cytokine inducer PPD, polyI:C and PHA [Dissertation]. Chongqin: Chongqin Medical University, 2008.
  • 45
    Han Q, Zhang C, Zhang J, Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 2011;54:117989.
  • 46
    Wu YY. The regulation of HBcAg and TBKl on production of IFN-β induced by dsRNA in hepatocytes [Dissertation]. Hangzhou: Zhejiang University, 2008.
  • 47
    Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:113240.
  • 48
    Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91:208090.
  • 49
    Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010;185:115868.
  • 50
    Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 2011;85:98795.
  • 51
    Wang X, Li Y, Mao A, Li C, Tien P. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol 2010;7:3418.
  • 52
    Jiang J, Tang H. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 2010;1:110617.
  • 53
    Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:2005963.
  • 54
    Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011;1:51925.
  • 55
    Liu M, Hao Y, Ding H, Yang D, Lu M. Interleukin-10 is expressed in HepG2.2.15 cells and regulated by STAT1 pathway. J Huazhong Univ Sci Technolog Med Sci 2011;31:62531.
  • 56
    Fan HB, Guo YB, Wang BJ, et al. Expression of IFN-α/β receptor in the PBMCs and liver of patients with hepatitis B and its clinical significance. J South Med Univ 2008;28:97981.
  • 57
    Ren SP Effect of hepatitis B virus on expression of type I interferon receptor [Dissertation]. Hangzhou: Zhejiang University, 2000.
  • 58
    Chung Y-H. Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med 2012;29:5816.
  • 59
    Guan SH, Lu M, Grunewald P, Roggendorf M, Gerken G, Schlaak JF. Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment. World J Gastroenterol 2007;13:22835.
  • 60
    Xiong W. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication [D] [Dissertation]. Shanghai: Fudan University, 2004.
  • 61
    Wang X. Interaction of hepatitis B virus with interferon-α inducible cellular proteins [Dissertation]. Shanghai: Fudan University, 2004.
  • 62
    Wu M. Mechanisms of inhibiting interferon-inducible MyD88 hepatitis B virus [Dissertation]. Shanghai: Fudan University, 2007.
  • 63
    Lin SS. Molecular mechanisms of the inhibition of HBV gene replication by MyD88 protein [Dissertation]. Shanghai: Fudan University, 2007.
  • 64
    Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 2007;88:32609.
  • 65
    Yu SY. Preliminary study on mechanisms of interfering with IFN-α induced signaling pathway by hepatitis B virus [Dissertation]. Shanghai: Fudan University, 2005.
  • 66
    Wang L. The anti-IFN-α effects of the Tp associated protein of hepatitis B virus [Dissertation]. Fuzhou: Fujian Medical University, 2009.
  • 67
    Guan SH, Yang K, Pan Y. Study of the effect of hepatitis B virus on interferon-induced antiviral proteins expression. Acta Universitatis Medicinalis Anhui 2011;46:3247.
  • 68
    Guan SH, Yang K, Lu MJ, Lu YP, Yang DL. The influence of HBV and its antigens on the expressions of JAK-STAT signal transduction pathway molecules and antiviral proteins of IFN alpha. Chin J Hepatol 2011;19:4404.
  • 69
    Siebler J, Protzer U, Wirtz S, et al. Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication. Eur J Gastroenterol Hepatol 2006;18:16774.
  • 70
    Zhang Q, Wang Y, Wei L, et al. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro. J Gastroenterol Hepatol 2008;23:174761.
  • 71
    Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007;46:55865.
  • 72
    Li J, Chen F, Zheng M, et al. Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. Antiviral Res 2010;85:4639.
  • 73
    Cheng ZL, Guan SH, Yang K, Pan Y. Effect of SOCS1 on the antiviral replication of interferon-α. Acta Universitatis Medicinalis Anhui 2011;46:22830.
  • 74
    Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011;8:354.
  • 75
    Fish EN, Uddin S, Korkmaz M, Majchrzak B, Druker BJ, Platanias LC. Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem 1999;274:5713.
  • 76
    Uddin S, Lekmine F, Sharma N, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000;275:2763440.
  • 77
    Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999;274:3012731.
  • 78
    Uddin S, Sassano A, Deb DK, et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002;277:1440816.
  • 79
    Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011;31:7987.
  • 80
    Li N, Zhang L, Chen L, et al. MxA inhibits hepatitis B virus replication by interaction with core protein HBcAg. Hepatology 2012;56:80311.
  • 81
    Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001;75:268491.
  • 82
    Yang K. Primary research of the antagonistic action of HBV and its antigen components on the antiviral activity of interferon-α [Dissertation]. Hefei: Anhui Medical University, 2010.
  • 83
    Rosmorduc O, Petit MA, Pol S, et al. In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology 1995;22:109.
  • 84
    Fernandez M, Quiroga JA, Carreno V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003;84:207382.
  • 85
    Rosmorduc O, Sirma H, Soussan P, et al. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 1999;80(Pt 5):125362.
  • 86
    Yang YL, Reis LF, Pavlovic J, et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995;15:14.
  • 87
    Park I-H, Baek K-W, Cho E-Y, Ahn B-Y. PKR-dependent mechanisms of interferon-α for inhibiting hepatitis B virus replication. Mol Cells 2011;32:16772.
  • 88
    Chen GG, Lai PB, Ho RL, et al. Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus. J Med Virol 2004;73:18794.
  • 89
    Han Q, Zhang C, Zhang J, Tian Z. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS ONE 2011;6:e27931.
  • 90
    Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011;16:116986.
  • 91
    Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:100913.
  • 92
    Ma JC, Wang LW, Li XJ, Liao YF, Hu XY, Gong ZJ. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha. Hepatobiliary Pancreat Dis Int 2007;6:16671.
  • 93
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMA. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol 2011;19:1324.
  • 94
    Shao G. Experiment study on the mutant mechanism of HBV C gene with the treatment of IFN in vitro and application of HepG2.2.15 cell [Dissertation]. Guangzhou: Sun Yat-sen University, 2006.
  • 95
    Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13:61324.
  • 96
    Wang WF, Zhou XD. An in vitro study on the mutant of HBV treated with interferon. Chin J Hepatol 2005;13:7934.
  • 97
    Liu Y, Ni X. Relationship between the replication of hepatitis B virus and HBV precoremutation in chronic hepatitis B patients. Hebei Med J 2007;29:10568.
  • 98
    Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:45362.
  • 99
    Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993;18:7819.
  • 100
    Schildgen O. Host factors may influence response to antiviral therapy in chronic hepatitis B virus infections. Med Hypotheses 2011;76:41720.
  • 101
    Kong XF. Study on the correlation between interferon signal transduction systems and hepatitis B [Dissertation]. Shanghai: Shanghai Second Medical University, 2004.